Paradigm Biopharmaceuticals Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was AUD 0.04676 million compared to AUD 0.079224 million a year ago. Net loss was AUD 51.91 million compared to AUD 39.25 million a year ago.

Basic loss per share from continuing operations was AUD 0.2078 compared to AUD 0.1687 a year ago. Diluted loss per share from continuing operations was AUD 0.2078 compared to AUD 0.1687 a year ago.